rease as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. however, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses. there is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying disease process. the effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. given these considerations, antipsychotics should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that, 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. in patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. the need for continued treatment should be reassessed periodically. if signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. however, some patients may require treatment despite the presence of the syndrome. (for further information about the description of tardive dyskinesia and its clinical detection, please refer to the section on adverse reactions .) falls molindone hydrochloride may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. for patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. neuroleptic malignant syndrome (nms) a potentially fatal symptom complex sometimes referred to as neuroleptic malignant syndrome (nms) has been reported in association with antipsychotic drugs. clinical manifestations of nms are hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). the diagnostic evaluation of patients with this syndrome is complicated. in arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (eps). other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (cns) pathology. the management of nms should include, 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. there is no general agreement about specific pharmacological treatment regimens for uncomplicated nms. if a patient requires antipsychotic drug treatment after recovery from nms, the potential reintroduction of drug therapy should be carefully considered. the patient should be carefully monitored, since recurrences of nms have been reported.

actin levels; the elevation persists during chronic administration. tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported, the clinical significance of elevated serum prolactin levels is unknown for most patients. an increase in mammary neoplasms has been found in rodents after chronic administration of antipsychotic drugs. neither clinical studies nor epidemiologic studies conducted to date, however, have shown an association between chronic administration of these drugs and mammary tumorigenesis; the available evidence is considered too limited to be conclusive at this time. molindone hydrochloride has not been shown effective in the management of behavioral complications in patients with mental retardation.

toms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. an elevated risk of acute dystonia is observed in males and younger age groups. tardive dyskinesia antipsychotic drugs are known to cause a syndrome of dyskinetic movements commonly referred to as tardive dyskinesia. the movements may appear during treatment or upon withdrawal of treatment and may be either reversible or irreversible (i.e., persistent) upon cessation of further antipsychotic administration. the syndrome is known to have a variable latency for development and the duration of the latency cannot be determined reliably. it is thus wise to assume that any antipsychotic agent has the capacity to induce the syndrome and act accordingly until sufficient data has been collected to settle the issue definitively for a specific drug product. in the case of antipsychotics known to produce the irreversible syndrome, the following has been observed. tardive dyskinesia has appeared in some patients on long-term therapy and has also appeared after drug therapy has been discontinued. the risk appears to be greater in elderly patients on high-dose therapy, especially females. the symptoms are persistent and in some patients appear to be irreversible. the syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). there may be involuntary movements of extremities. there is no known effective treatment of tardive dyskinesia; antiparkinsonism agents usually do not alleviate the symptoms of this syndrome. it is suggested that all antipsychotic agents be discontinued if these symptoms appear. should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked. it has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time the syndrome may not develop (see warnings ). autonomic nervous system occasionally blurring of vision, tachycardia, nausea, dry mouth and salivation have been reported. urinary retention and constipation may occur particularly if anticholinergic drugs are used to treat extrapyramidal symptoms. one patient being treated with molindone hydrochloride experienced priapism which required surgical intervention, apparently resulting in residual impairment of erectile function. laboratory tests there have been rare reports of leucopenia and leucocytosis. if such reactions occur, treatment with molindone hydrochloride may continue if clinical symptoms are absent. alterations of blood glucose, b.u.n., and red blood cells have not been considered clinically significant. metabolic and endocrine effects alteration of thyroid function has not been significant. amenorrhea has been reported infrequently. resumption of menses in previously amenorrheic women has been reported. initially heavy menses may occur. galactorrhea and gynecomastia have been reported infrequently. increase in libido has been noted in some patients. impotence has not been reported. although both weight gain and weight loss have been in the direction of normal or ideal weight, excessive weight gain has not occurred with molindone hydrochloride. hepatic effects there have been rare reports of clinically significant alterations in liver function in association with molindone hydrochloride use. cardiovascular rare, transient, non-specific t wave changes have been reported on e.k.g. association with a clinical syndrome has not been established. rarely has significant hypotension been reported. ophthalmological lens opacities and pigmentary retinopathy have not been reported where patients have received molindone hydrochloride. in some patients, phenothiazine induced lenticular opacities have resolved following discontinuation of the phenothiazine while continuing therapy with molindone hydrochloride. skin early, non-specific skin rash, probably of allergic origin, has occasionally been reported. skin pigmentation has not been seen with molindone hydrochloride usage alone. molindone hydrochloride has certain pharmacological similarities to other antipsychotic agents. because adverse reactions are often extensions of the pharmacological activity of a drug, all of the known pharmacological effects associated with other antipsychotic drugs should be kept in mind when molindone hydrochloride is used. upon abrupt withdrawal after prolonged high dosage an abstinence syndrome has not been noted.

s and feeding disorder in these neonates. these complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization. molindone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

less than 2 to 3% unmetabolized molindone hydrochloride tablets being excreted in urine and feces.

nc. ‡ artane is a registered trademark of lederle laboratories. § cogentin is a registered trademark of merck & co., inc. ¶ akineton is a registered trademark of knoll laboratories. distributed by: epic pharma, llc laurelton ny, 11413 rev. 04-2018-00 mf336rev04/18 oe2798